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The Journal of Immunology
Aneurysmal Lesions of Patients with Abdominal Aortic
Aneurysm Contain Clonally Expanded T Cells
Song Lu,* John V. White,† Wan Lu Lin,* Xiaoying Zhang,* Charalambos Solomides,‡
Kyle Evans,* Nectaria Ntaoula,* Ifeyinwa Nwaneshiudu,* John Gaughan,x
Dimitri S. Monos,{,‖ Emilia L. Oleszak,#,1 and Chris D. Platsoucas*,1
Abdominal aortic aneurysm (AAA) is a common disease with often life-threatening consequences. This vascular disorder is
responsible for 1–2% of all deaths in men aged 65 years or older. Autoimmunity may be responsible for the pathogenesis of
AAA. Although it is well documented that infiltrating T cells are essentially always present in AAA lesions, little is known about
their role in the initiation and/or progression of the disease. To determine whether T cells infiltrating AAA lesions contain clonally
expanded populations of T cells, we amplified b-chain TCR transcripts by the nonpalindromic adaptor–PCR/Vb-specific PCR
and/or Vb-specific PCR, followed by cloning and sequencing. We report in this article that aortic abdominal aneurysmal lesions
from 8 of 10 patients with AAA contained oligoclonal populations of T cells. Multiple identical copies of b-chain TCR transcripts
were identified in these patients. These clonal expansions are statistically significant. These results demonstrate that ab TCR+
T lymphocytes infiltrating aneurysmal lesions of patients with AAA have undergone proliferation and clonal expansion in vivo at
the site of the aneurysmal lesion, in response to unidentified self- or nonself Ags. This evidence supports the hypothesis that AAA is
a specific Ag–driven T cell disease. The Journal of Immunology, 2014, 192: 000–000.
A
bdominal aortic aneurysm (AAA) is a common disease
characterized by the presence of aortic dilations with
diameter. 3 cm (1.5 times greater than the normal artery).
As the diameter of the AAA grows beyond 5.0 cm, there is an
increasing risk for rupture. The mortality associated with ruptured
AAA may be as high as 80–90% (1–3). AAA is present in 3% of
those aged$60 y and is responsible for 1–2% of all deaths in men
aged 65 y or older (3). AAA is among the 10 leading causes of
death among 55–74-y-olds and is the 13th leading cause of death
in the United States (all ages) (3).
Although genetic and environmental factors are involved, our
understanding of the etiology and pathogenesis of AAA is limited
(4–6). AAA is a complex multifactorial disease (4–6). Autoim-
munity may be responsible for the pathogenesis of AAA. AAA
may be an autoimmune disease. This is supported by the following.
i) The presence of inflammatory mononuclear cell infiltrates in
AAA lesions, consisting mostly of T and B cells, NK cells, and
macrophages (7–9). These inflammatory infiltrates are particularly
profound in the adventitia. Also, inflammatory AAA contains nu-
merous inflammatory cells arranged in follicles, suggesting a cell-
mediated Ag response (7). ii) Mononuclear cells infiltrating AAA
lesions express early (CD69), intermediate (CD25, CD38), and
late (CD45RO, HLA class II) activation Ags, demonstrating an
active ongoing inflammatory response in these lesions (9). iii)
AAA is associated with particular HLA alleles (10, 11). iv) IgG
Ab purified from the wall of AAAs is immunoreactive with pro-
teins isolated from normal aortic tissue (12, 13). v) Putative self-
and nonself AAA Ags have been identified, including elastin and
elastin fragments (14–16), collagen types I and III (reviewed in
Ref. 4), aortic AAA protein 40 (also known as microbial-associated
glycoprotein 36) (12, 13, 17), oxidized low-density lipoprotein (18),
Chlamydia pneumoniae (19, 20), Treponema palladium (21), and
CMV (22). Molecular mimicry, which is defined as the sharing of
antigenic epitopes between microorganisms and host Ags (23),
may be responsible for inducing T cell inflammatory responses in
AAA. vi) Proinflammatory Th1 cytokines play an important role
in the pathogenesis of AAA; however, production of Th2 cyto-
kines also has been reported (reviewed in Ref. 4; 24–26).
Although infiltrating T cells are essentially always present in
AAA lesions (7–9), little is known about the role of T cells in the
initiation and progression of AAA. The CD4+/CD8+ ratio in AAA
lesions is 2–4-fold higher than in normal peripheral blood, indi-
cating a redistribution or expansion of certain T cell subtypes in
AAA (7–9). Determination of whether mononuclear cells infiltrating
AAA lesions contain oligoclonal populations of T cells (i.e., clonally
expanded T cells in response to specific Ag [self or nonself]), and
eventually the identification of the Ag(s) that they recognize, is
critical for our understanding of the pathogenesis of AAA.
We report in this article that AAA lesions contain clonally
expanded T cells. Substantial proportions of identical b-chain TCR
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transcripts were found in these lesions, after PCR amplification
followed by cloning of the amplified transcripts and sequencing.
Their presence can be explained only by proliferation and clonal
expansion in vivo of the corresponding T cell clones in response to
specific, as yet unidentified Ag(s) (27). These results strongly
suggest that AAA is a specific Ag–driven T cell disease.
Materials and Methods
Patients
AAA specimens were obtained from patients undergoing surgery for repair
of infrarenal AAAs. AAA size, gender, race, age, past and recent history of
associated diseases, and cardiovascular risk factors of the patients are shown
in Table I. All adherent blood clots were carefully stripped away from the
aneurysm walls prior to use. Grossly normal infrarenal abdominal aortic
specimens from patients who died of nonvascular causes were obtained at
autopsy and used as controls. Venous peripheral blood was obtained from
healthy donors. These studies were reviewed and approved by the Insti-
tutional Review Boards of the Advocate Lutheran General Hospital and
Temple University Hospital.
Immunohistochemistry
Each AAA specimen was divided into two fractions. One was embedded
onto OCT, snap-frozen in liquid nitrogen, and stored at 270˚C for immu-
nohistochemistry. The remaining specimen was either snap-frozen in liquid
nitrogen or used fresh for preparation of RNA. Immunostaining was carried
out using an anti-CD3 mAb (clone NCL-CD3-PS1; Novocastra, Newcastle-
upon-Tyne, U.K.), an anti-CD4 mAb (clone 4B12; Dako, Glostrup, Den-
mark), and an anti-CD8 mAb (clone C8/144B; Dako) by the avidin-biotin
complex–immunoperoxidase method (Vector Labs, Burlingame, CA), as
described (28, 29).
Preparation of single-cell suspensions from aortic specimens
with AAA lesions
Fresh aortic specimens containing AAA lesions from patients with AAA
were dissected into 2 mm3 blocks in a petri dish and incubated with col-
lagenase (0.5 mg/ml) and DNase (120 U/ml) for 1 h at 37˚C. The digested
tissue and supernatant were passed through a cell strainer (30 mm). A single-
cell suspension was obtained by incubating for an additional 10 min in
trypsin-EDTA solution. Mononuclear cells were isolated using a Ficoll-
Paque density cushion (30).
Isolation of CD4+ and CD8+ T cells from AAA specimens
CD4+ and CD8+ T cells were isolated from single-cell suspensions from
AAA lesions using Dynabeads (Dynal Biotech, Brown Deer, WI). Single
cell suspensions were divided into two aliquots, and one was used for
the isolation of CD4+ T cells by employing the CD4+ Isolation Kit (Dynal
Biotech), and the other aliquot was used for the isolation of CD8+ T cells
by employing the CD8+ Isolation Kit (Dynal Biotech) following the manu-
facturer’s specifications. DETACHaBEAD was used to release CD4+ or CD8+
T cells, as recommended by the manufacturer (http://tools.lifetechnologies.
com/content/sfs/manuals/DETACHaBEAD%20CD4-CD8.pdf).
Isolation of PBMCs from healthy donors
PBMCs were used as methodological control and were isolated from pe-
ripheral blood using a Ficoll-Hypaque density cushion (30).
DNA-based HLA typing for HLA-DRB1, HLA-DQA1, and
HLA-DQB1
DNAwas extracted from aortic specimens of patients with AAA for DNA-
based typing of DRB1, DQA1, and DQB1 loci (31). Samples were typed at
HLA-DRB1 (exon 2) and HLA-DQB1 (exons 2 and 3) with AlleleSEQR
typing reagents (Abbott Molecular, Des Plaines, IL). Sequencing was
performed using an ABI 3130 sequencer (Applied Biosystems, Foster City,
CA), and the results were analyzed using Assign-SBT v3.5 Software
(Conexio Genomics, Fremantle, Australia). DQA1 and any remaining
ambiguities were resolved by sequence-specific primer typing (SSP Uni-
Tray; Invitrogen, Carlsbad, CA and Olerup-SSP; QIAGEN, Valencia, CA).
RNA isolation
Total RNAwas prepared from fresh (cryopreserved) aorta tissue from AAA
lesions from patients with AAA, PBMCs, CD4+ cells, or CD8+ cells using
a solution of guanidinium thiocyanate (Stratagene, La Jolla, CA), as rec-
ommended by the manufacturer.
Synthesis of cDNA
cDNAwas synthesized from total RNA and primed with oligo-(dT)15-NotI
(Promega), using SuperScript II (Gibco/Brl), following the manufacturer’s
instructions (32–37). Double-stranded cDNA was blunt ended for efficient
adaptor ligation by adding T4 DNA polymerase.
Amplification by the nonpalindromic adaptor PCR/Vb-specific
PCR
Adaptor ligation and NotI digestion. The blunt-ended cDNAwas ligated at
both the 59 and 39 blunt ends with an equivalent molar concentration of
a nonpalindromic adaptor (NPA) (32–37) by incubation for 14 h at 16˚C
with T4 DNA ligase (Life Technologies-BRL). This adaptor, a modifica-
tion of the one previously described (32–37), consists of two oligonu-
cleotides (Supplemental Table I), the 59-AATTCGAACCCCTTCGAGAA-
TGCG-39 and its complementary 39-GCTTGGGGAAGCTCTTACGC-p-59,
preannealed to each other. The ligated adaptor was removed from the 39 end
of the double-stranded cDNA by digestion with NotI restriction endonu-
clease, as described (32–37), while it remained in the 59 end. The digested
cDNA was purified using a G-50 column (59-39, Boulder, CO), as recom-
mended by the manufacturer.
First cycle of amplification by NPA-PCR. NPA-PCR was carried out as
previously described (32–37), with minor modifications. The NPA 59-
AATTCGAACCCCTTCGAGAATGCT-39 was used as the 59 amplification
primer. The 39 amplification primer hCb3 was located in the Cb region,
starting at nucleotide 208 (Supplemental Table I). The purified NotI-
digested cDNAwas amplified by NPA-PCR in 100 ml, which contained,
in addition to the primers and cDNA, 5 U native PFU DNA polymerase
and 1 mM deoxynucleotide triphosphates in 13 buffer. The cDNAwas
denatured at 95˚C for 5 min and amplified by 30 cycles of PCR at 94˚C
for 1 min, 45˚C for 1 min, and 72˚C for 2 min, with a final extension at
72˚C for 7 min. The amplified transcripts were purified using a G-50
column, as described above.
Second cycle of amplification by individual Vb-specific PCR. Vb-specific
PCRs were carried out using, as a template, 4 ml b-chain TCR cDNA,
which had been amplified previously by NPA-PCR, as described. Single
oligonucleotides, each specific for 1 of 24 Vb families (32–37) (Supplemental
Table I), were used each as 59 end amplification primer in 24 separate
amplifications. A Cb primer designated as hCb2 was used as 39 amplifi-
cation primer, and it was located in the Cb region starting at nucleotide
113, 59 to the hCb3 primer used for the first (NPA-PCR) amplification
(nested design). This design eliminates the possible amplification of other
members of the Ig supergene family, which may share homology with the
b-chain TCR transcript, because it is unlikely that the same molecule,
member of the Ig supergene family, has substantial homology with the
b-chain TCR transcript at both the hCb3 and hCb2 sites. The reaction
mixture of 50 ml contained, in addition to the primers and cDNA, 2.5 U
native PFU DNA polymerase and 1 mM deoxynucleotide triphosphates in
13 buffer. It was denatured at 95˚C for 5 min and amplified by 30 cycles
of PCR at 94˚C for 1 min, 55˚C for 1 min, and 72˚C for 2 min, followed by
a 7-min final extension at 72˚C.
Vb-specific PCR amplification
Vb-specific PCR amplifications were carried out as described (32–37) to
examine, in more detail, a single Vb family or subfamily or to confirm the
clonal expansions observed by NPA-PCR/Vb-specific PCR. Vb3, Vb6,
Vb12, Vb14, and Vb24 families were amplified by Vb-specific PCR. 59
and 39 (hCb2) amplification primers are shown in Supplemental Table I.
Template cDNA was synthesized from total RNA isolated from the same
AAA specimen used for NPA-PCR/Vb-specific PCR or from total RNA
from the same specimen isolated separately. cDNAwas denatured at 95˚C
for 5 min and amplified by 35 cycles of PCR, as described above.
Cloning and sequencing of PCR products
To reduce the workload for cloning and sequencing of the NPA-PCR/Vb-
specific PCR amplified TCR transcripts, 8 ml from each of the 24 NPA-
PCR/Vb-specific PCR products was mixed and incubated with Taq poly-
merase at 72˚C for 10 min to add an adenine at the 39 end. The mixture
(192 ml) was size selected by agarose gel electrophoresis and purified with
a GENECLEAN Kit (Bio101, Vista, CA). The purified NPA-PCR/Vb-
specific PCR or Vb-specific PCR products were cloned into the TOPO-TA
cloning vector (Invitrogen), transformed into Top10 One Shot Chemically
Competent cells (Invitrogen), according to the manufacturer’s instructions,
and subjected to blue-white screening. The competent cells were incubated
for 30–45 min with the vector on ice, submitted to heat shock for 30–45 s
at 42˚C, incubated for 2 min on ice, added to 250 ml SOC medium (32–

















36), incubated for 1 h at 37˚C, and plated onto X-gal–containing agar
plates. White colonies were picked out using the PerfectPrep Plasmid Mini
Kit (Eppendorf, Westbury, NY), as recommended by the manufacturer.
Plasmids were sequenced by the dideoxy chain termination method on 6%
polyacrylamide DNA sequencing gels using an ABI373A DNA Sequencer
(Applied Biosystems). Large numbers of white colonies were obtained.
Comparable numbers of TCR clones were obtained after NPA-PCR/Vb-
specific PCR and cloning and after each Vb-specific PCR and cloning. The
maximum theoretical number of unique b-chain TCR transcripts is esti-
mated to be 1012 (38). Because this number is so large, the probability of
finding, by chance, two identical copies of a single b-chain TCR transcript
in an independent sample of T cells is negligible. However, during
transformation of Escherichia coli, the plasmid/cell mixture was subjected
to heat shock, followed by growth for 1 h in SOC medium at 37˚C before
plating the colonies. Under log-phase growth (ideal growth conditions),
E. coli can undergo a division in 20 min, which could result in two doublings
within 60 min (39). However, because of the heat shock, E. coli does not
immediately enter the log phase, although the unlikely possibility for a few
E. coli–transformed cells to double before plating does exist. Therefore,
a doublet (i.e., identical TCR transcript sequences from two different
colonies) may be the result of a single transfected E. coli that doubled
before plating, or it may reveal a clonal expansion. In the statistical analysis,
we addressed this issue. However, doubling of singly transfected E. coli
before plating is infrequent. We amplified (by NPA-PCR, NPA-PCR/Vb-
specific PCR, or Vb-specific PCR), cloned, and sequenced 488 b-chain
TCR transcripts from PBMCs from healthy donors. All b-chain TCR
transcripts were unique compared with each other, with the exception of
seven b-chain TCR clones that appeared in duplicate (1.4%) (32–37).
Computer analysis and comparison of sequences
The nucleic acid sequence of TCR transcripts encoding for the V, D, J, and C
region was compared with those in the National Center for Biotechnology
Information databases using the standard nucleotide–nucleotide basic local
alignment search tool (BLAST) program, as described (32–37). The nu-
cleotide sequence of the N-D-N region of each b-chain TCR transcript was
identified as the sequence between the last discernible Vb nucleotide and
the first discernible Jb nucleotide. The deduced amino acid sequences in
the CDR3 regions were compared with those in the National Center for
Biotechnology Information nr database, using the BLAST program to
search for short, nearly exact matches. There is no information on the
maximum number of CDR3 amino acid differences that permit substantial
CDR3 homology. Differences of two conservative and one nonconserva-
tive amino acids were chosen arbitrarily as the maximum number of dif-
ferences allowed between CDR3 motifs from different T cell clones to
define substantial CDR3 homology.
Statistical analysis
We used the binomial distribution (34, 36) to calculate the probability of
the number (x) of the multiple copies of the identical transcripts that have
been identified (x/n; n = total number of transcripts sequenced) against the
alternative hypothesis that each transcript is expressed only once [i.e., all
transcripts are unique when compared with each other (1/n)] or against
a second alternative hypothesis that a single b-chain TCR transcript is only
expressed twice, and all other transcripts sequenced are expressed only
once (2/n). The alternative and the second alternative hypotheses were
developed using results obtained by NPA-PCR/Vb-specific PCR, NPA-
PCR, or Vb-specific PCR amplification of b-chain TCR transcripts from
PBMCs from healthy donors, cloning, and sequencing (32–37). Each
b-chain TCR transcript from these PBMC is expressed only once (all
transcripts are unique when compared with each other; 1/n) or a single
transcript is expressed twice, and all other b-chain TCR transcripts se-
quenced are expressed only once (all transcripts except one are unique
when compared with each other; 2/n).
Results
T cells are infiltrating AAA lesions
Representative pathology and immunohistochemical staining with
anti-CD3, anti-CD4, or anti-CD8 mAbs of AAA tissue is shown
in Fig. 1. Substantial proportions of infiltrating CD3+ T cells are
present in AAA lesions and, in particular, in the adventitia and
media, and they are comprised of CD4+ and CD8+ cells, as described
(9–11). Grossly normal infrarenal abdominal aortic specimens
obtained at autopsy from patients who died of nonvascular causes
rarely showed, if any, mononuclear cell infiltrates (data not shown).
Oligoclonal T cells are infiltrating AAA lesions from patients
with AAA
To determine whether fresh (not expanded in culture) mononuclear
cells infiltrating AAA lesions contain oligoclonal T cell popula-
tions, b-chain TCR transcripts were amplified, cloned, and se-
quenced from 10 AAA specimens (Table I). All sequences obtained
were compared with those from the GenBank database using the
BLAST program. More than 97% of the sequences obtained were
typical of productively rearranged human b-chain TCR transcripts,
were novel, and were not reported in the GenBank database. The
remaining,3% of these sequences were unproductively rearranged
and were not included in the analysis. Sequence analysis revealed
substantial proportions of identical b-chain TCR transcripts in
AAA specimens from 8 of 10 patients, demonstrating the presence
of oligoclonal populations of T cells in these aneurysmal lesions.
Sequence analysis of b-chain TCR transcripts from AAA lesions
from patient AAA09 after NPA-PCR/Vb-specific PCR revealed
8 of 38 transcripts (21%) (clone 09-02) (Vb14.1Db2.1Jb2.3)
(CDR3:LASGA) (Table II). These results were statistically sig-
nificant by the bimodal distribution. The probability of the appear-
ance of the 8/38 observed identical transcripts against the alternative
hypothesis, that each b-chain TCR transcript is expressed only once
(1/n = 1/38), was p , 0.0001 or against the alternative hypothesis,
that a single transcript is only expressed twice and all other TCR
transcripts sequenced are expressed only once (2/n = 2/38), was p,
0.0006. Three other TCR clones appeared in duplicate. The re-
maining transcripts were unique when compared with each other
(Table II). The Vb14.1Db2.1Jb2.3 clonal expansion was con-
firmed by Vb14-specific PCR, followed by cloning and sequencing;
12 of 21 (57%; p , 0.0001) Vb14 transcripts were identical to the
clonally expanded 09-02 clone found by NPA-PCR/Vb-specific
PCR (Table II). The remaining transcripts were unique when com-
pared with each other.
Sequence analysis of b-chain TCR transcripts from AAA
lesions from patient AAA00 after NPA-PCR/Vb-specific PCR
revealed 6 of 34 identical transcripts (18%; p = 0.0004) (clone
00-03) (Vbb.1Db2.1Jb2.7) (CDR3:VGGGV) (Table II). Three
clones were expressed in triplicate, three were expressed in duplicate,
and the remaining 13 were unique when compared with each other.
NPA-PCR/Vb-specific PCR of b-chain TCR transcripts from
AAA lesions from patient AAA03, followed by cloning and se-
quencing, revealed that clone 03-11 was expressed in three copies
(Vb24.1Db1.1Jb1.3) (CDR3:RSGLL) (p = 0.06), and two clones
were expressed in duplicate (Table II). The remaining 17 clones
were unique when compared with each other. Separate Vb24-,
Vb6-, Vb12-, and Vb3-specific PCR amplifications, followed by
cloning and sequencing, revealed the following, respectively, a
Vb24 clone (#03-11) accounting for 17 of 20 identical tran-
scripts (85%; p , 0.0001) that was identical to clone 03-11
(Vb24.1Db1.1Jb1.3) (CDR3:RSGLL), previously identified by
NPA-PCR/Vb-specific PCR; a Vb6 clone (#03-02) accounting for
4 of 21 identical transcripts (19%; p = 0.01); three Vb12 clones
expressed in triplicate (p = 0.06); and a Vb3 clone (#03-04) ac-
counting for 5 of 24 identical transcripts (21%; p , 0.002)
(Table II).
Sequence analysis of b-chain TCR transcripts from AAA
lesions from patient AAA06 after NPA-PCR/Vb-specific PCR and
cloning revealed that clone 06-01 had 24 of 41 identical transcripts
(59%; p , 0.0001) (Vb22.1Db2.1Jb2.1) (CDR3:KEGLA LG);
clone 06-03 had 8 of 41 identical transcripts (20%; p , 0.0001)
(Vb3.1Db2.1Jb2.1) (CDR3:LFLA ATDH); and clone 06-12 had 6
of 41 identical transcripts (15%; p = 0.0004) (Vb20.1Db1.1Jb1.2)
(CDR3:WTGG) (Table II).

















Sequence analysis of b-chain TCR transcripts from AAA
lesions from patient AAA10 after NPA-PCR/Vb-specific PCR and
cloning revealed 3 of 26 identical transcripts (11.5%; p = 0.06)
(clone 10-07) (Vb14.1Db2.1Jb2.1) (CDR3:LGVSWTSGDSV)
(Table II). The remaining 23 transcripts were unique when com-
pared with each other. Vb3-specific PCR amplification, followed
by cloning and sequencing, showed 10 of 41 identical transcripts
(24%; p , 0.0001) (clone 10-09) (Vb3.1Db2.1Jb2.1) (CDR3:
SSPARTGSA) and 6 of 41 identical transcripts (15%; p = 0.0004)
(clone 10-03) (Vb3.1Db1.1Jb1.5) (CDR3:TTSGGGRR) (Table II).
Other clones were expressed in duplicate or were unique when
compared with each other. Vb14-specific PCR revealed that 3 of
21 transcripts were identical (14%; p = 0.06) (clone 10-07)
(Vb14.1Db2.1Jb2.1) (CDR3:LGVSWTSG DSV) (data not shown).
This clone was first identified by NPA-PCR/Vb-specific PCR
(Table II).
NPA-PCR/Vb-specific PCR amplification of b-chain TCR tran-
scripts from patients AAA12, AAA04, AAA02, and AAA07, fol-
lowed by cloning and sequencing, did not reveal statistically
significant clonal expansions (Table II). However, Vb3-specific
PCR, followed by cloning and sequencing from AAA lesions
from patient AAA04, revealed 4 of 22 identical transcripts (18.2%;
p = 0.014) (clone 04-09) (Vb3.1Db2.1Jb2.7) (CDR3:CASSLG-
SYEQYF). Vb6-specific PCR, followed by cloning and sequencing,
showed that clone 07-04 (patient AAA07) accounted for 4 of 19
identical transcripts (21%; p = 0.013) (Vb6.3Db2.1Jb2.3) (CDR3:
PVGQST DTQYF). Clone 07-05 was present in triplicate (p =
0.06) (Vb6.2Db2.1Jb2.1) (VLVG NEQFF).
b-chain TCR transcripts from purified CD4+ and CD8+ T cells
from AAA lesions from patient AAA14 were amplified by NPA-
PCR/Vb-specific PCR, followed by cloning and sequencing. Two
clonal expansions were found in purified CD4+ T cells: clone 14-02
accounted for 7 of 15 identical transcripts (47%; p , 0.0001)
(Vb2.1Db2.1Jb2.1) (CDR3:CSARDLAGNEQFF), and clone
14-01 accounted for 5 of 15 identical transcripts (33%; p = 0.002)
(Vb18.1Db1.1Jb2.7) (CDR3:CASSPKTGISYEQYF) (Table III).
These results suggest the presence of strong clonal expansions of
CD4+ T cells infiltrating AAA lesions. Sequence analysis of b-chain
TCR transcripts from purified CD8+ T cells from AAA lesions from
patient AAA14 after NPA-PCR/Vb-specific PCR revealed two TCR
clones: clone 14-13 (Vb18.1Db2.1Jb2.2) (CDR3:CASSPYGGA)
and clone 14-99 (Vb2.1Db1.1Jb2.4) (CDR3:CSASLDSWTQET).
Each accounted for 3 of 14 identical transcripts (21%; p = 0.06).
The remaining eight transcripts were unique (Table IV).
RNA from grossly normal infrarenal abdominal aortic specimens
from three patients who died of nonvascular causes were obtained
at autopsy and used as controls. NPA-PCR/Vb-specific PCR am-
plification did not reveal any b-chain TCR transcripts (data not
shown). These results are in agreement with those of other inves-
tigators (7, 40, 41) who reported the absence of CD45+ cells or
T cells from nonaneurysmal aortic tissue. We (35) reported similar
results with control epicardial arteries.
PBMCs from normal donors contain polyclonal populations of
T cells
PBMCs from normal donors were used as methodological controls
to make certain that all PCR amplification, cloning, and sequencing
protocols were working well. Representative results of 104 b-chain
TCR transcripts are shown after NPA-PCR/Vb-specific PCR
(67 b-chain TCR transcripts) or Vb-specific PCR (37 b-chain TCR
transcripts), followed by cloning and sequencing (Table IV).
These sequences were unique when compared with each other,
except for one that appeared in duplicate, and are typical of poly-
clonal populations of T cells, in agreement with previous re-
ports (32–37). Similar results were obtained with a few hundred
T cell clones (32–37). b-chain TCR transcripts from purified
FIGURE 1. Immunohistochemical staining of AAA tissue using anti-CD3, anti-CD4, or anti-CD8 mAbs revealed CD3+ T cell infiltrates primarily in the arterial
wall, particularly in the adventitia (left panel). CD4+ (middle panel) and CD8+ (right panel) T cell infiltrates are also shown. Original magnification 3100.
Table I. Characteristics of the patients with AAA
Patient Gender Race Age (y)
AAA Size
(cm) HTN COPD TOB CHOL DM Other
AAA00 Male White 71 4.8 Yes No No No No
AAA02 Male White 65 5.8 Yes Yes Yes Yes No CAD
AAA03 Male White 80 5.5 Yes No No Yes No
AAA04 Male White 62 10.0 Yes No No Yes No CAD
AAA06 Male White 77 5.5 Yes No No No No CAD/Lymphoma
AAA07 Male White 71 5.5 No No No Yes Yes AOVR
AAA09 Male White 78 7.4 Yes Yes No No No CAD/CRI
AAA10 Male White 78 7.9 No No No Yes Yes CAD
AAA12 Male White 77 UN UN UN UN UN UN UN


























AOVR, aortic valve replacement; CAD, coronary artery disease; CHOL, high cholesterol; COPD, chronic obstructive pulmonary disease; CRI, chronic renal disease; DM;
diabetes mellitus; HTN, hypertension; TOB, current or former tobacco smoker; UN, unknown.

















Table II. b-chain TCR transcripts (CDR3 region) expressed in AAA lesions of patients with AAA
Clone Vb N-Db-N Jb
Transcript Frequency
in Specimen p Value
Patient AAA09





09-02 C A S S L L A S G A T D T Q Y F Vb14.1Db2.1Jb2.3 <0.0001 0.0006
tgtgccagcagttta ttggctagcggggc cacagatacgcagtatttt 8/38 (21.1%)
09-28 C A S S L D R G A E Q Y F Vb21.3Db2.1Jb2.7 0.19 0.28
tgtgccagcagctta gatcgaggagc cgagcagtacttc 2/38 (5.3%)
09-03 C S A N T G V G A F F Vb2.1Db1.1Jb1.1 0.19 0.28
tgcagtgct aacacaggggttgg agctttcttt 2/38 (5.3%)
09-21 C A S R K G Q G L S Y E Q Y F Vb3.1Db1.1Jb2.7 0.19 0.28
tgtgccagc agaaaaggacagggactc tcctacgagcagtacttc 2/38 (5.3%)





09-02 C A S S L L A S G A T D T Q Y F Vb14.1Db2.1Jb2.3 <0.0001 <0.0001
tgtgccagcagttta ttggctagcggggc cacagatacgcagtatttt 12/21 (57.1%)
Patient AAA00





00-03 C A S S L V G G G V S Y E Q Y F Vb5.1Db2.1Jb2.7 0.0004 0.01
tgcgccagcagcttg gttggtggcggggtc tcctacgagcagtacttc 6/34 (17.6%)
00-08 C A S S Q R G Q V N T D T Q Y F Vb9.2Db1.1Jb2.3 0.06 0.19
tgtgccagcagc cagaggggacaggtcaa cacagatacgcagtatttt 3/34 (8.8%)
00-12 C A S T F E R E L G Q P Q H F Vb13.3Db1.1Jb1.5 0.06 0.19
tgtgccagc acgtttgagcgggaattggg tcagccccagcatttt 3/34 (8.8%)
00-09 C A S S P R Q A Y T E A F F Vb18.1Db1.1Jb1.1 0.06 0.19
tgtgccagctca ccgaggcaggctt acactgaagctttcttt 3/34 (8.8%)
00-17 C S A I L T G G V N E Q Y F Vb2.1Db1.1Jb2.7 0.19 0.28
tgcagtgcc atactaacagggggcgtca acgagcagtacttc 2/34 (5.9%)
00-05 C A S S L Q G A Q S T G E L F F Vb3.1Db1.1Jb2.2 0.19 0.28
tgtgccagcagt ctacagggggcccagag caccggggagctgtttttt 2/34 (5.9%)
00-19 C S V E G L A G L A G P S S Y E Q Y F Vb4.1Db2.1Jb2.7 0.19 0.28
tgcagcgttgaa ggattggcgggactagcgggacctagc tcctacgagcagtacttc 2/34 (5.9%)
Patient AAA03





03-11 C A S S R S G L L S G N T I Y F Vb24.1Db1.1Jb1.3 0.06 0.19
tgtgccagcagcaga tcgggactgcta tctggaaacaccatatatttt 3/24 (12.5%)
03-17 C A S S P G G G G A N T E A F F Vb6.2Db1.1Jb1.1 0.19 0.28
tgtgccagcagt cccggggggggaggggcg aacactgaagctttcttt 2/24 (8.3%)
03-31 C A S S Q G L Y N E Q F F Vb12.2Db1.1Jb2.1 0.19 0.28
tgcgccagcagt cagggcct ctacaatgagcagttcttc 2/24 (8.3%)





03-11 C A T S R S G L L S G N T I Y F Vb24.1Db2.1Jb1.3 <0.0001 <0.0001
tgtgccaccagcaga tcgggactgcta tctggaaacaccatatatttt 17/20 (85.0%)
03-03 C A T S S R A G R L I G R A E A F F Vb24.1Db2.1Jb1.1 0.19 0.28
tgtgccaccagc agtcgggcgggacgtctcatcgggaggg ctgaagctttcttt 2/20 (10.0%)
03-07 C A T S R G Q G A Y G Y T F Vb24.1Db1.1Jb1.2 NS NS
tgtgccaccagc cggggacagggcgc ctatggctacaccttc 1/20 (5.0%)





03-02 C A S S Q N S G G A A N E Q F F Vb6.3Db2.1Jb2.1 0.01 0.09
tgtgccagcagc caaaattcggggggggccgcg aatgagcagttcttc 4/21 (19.0%)
03-08 C A S S L A R L D N E Q F F Vb6.2Db2.1Jb2.1 0.06 0.19
tgtgccagcagctta gcgaggctag acaatgagcagttcttc 3/21 (14.3%)
03-04 C A T R A L A G G Q T Q Y F Vb6.2Db2.1Jb2.5 0.19 0.28
tgtgcc acccgggcgctagcgggggggc agacccagtacttc 2/21 (9.5%)





03-15 C A I S E R G L Q F Y T F Vb12.1Db1.1Jb1.2 0.06 0.19
tgtgccatcagtgag cgggggctacagtt ctacaccttc 3/20 (15.0%)
03-05 C A T R L A G E T D T Q Y F Vb12.1Db2.1Jb2.3 0.06 0.19
tgtgcc accagactagcgggagag acagatacgcagtatttt 3/20 (15.0%)
03-02 C A I S E S G T S G S S E Q Y F Vb12.1Db2.1Jb2.7 0.06 0.19
tgtgccatcagtgag tcgggaactagcgggagctc cgagcagtacttc 3/20 (15.0%)
03-03 C A I S E S R G Q G L Y E Q Y F Vb12.1Db1.1Jb2.7 0.19 0.29
tgtgccatcagtgag tcgcggggacaggggct ctacgagcagtacttc 2/20 (10.0%)
03-09 C A T G T V R D Q P Q H F Vb12.1Db1.1Jb1.5 0.19 0.29
tgtgcc accgggaccgtcaggg atcagccccagcatttt 2/20 (10.0%)
(Table continues)

















Table II. (Continued )
Clone Vb N-Db-N Jb
Transcript Frequency
in Specimen p Value





03-04 C A S R L F L S S Y N E Q F F Vb3.1Db2.1Jb2.1 0.002 0.03
tgtgccagc aggctattcctgagc tcctacaatgagcagttcttc 5/24 (21%)
03-06 C A S S S P T P R T G D E Q Y V Vb3.1DbJb2.7 0.06 0.19
tgtgccagcagt tcccctaccccccggacagggg acgagcagtacgtc 3/24 (13%)
03-03 C A S S L G A R P Q E T Q Y F Vb3.1DbJb2.5 0.19 0.28
tgtgccagcagt ttaggggccagacct caagagacccagtacttc 2/24 (8%)
03-08 C A S S W G Q G N Y G Y T F Vb3.1DbJb1.2 0.19 0.28
tgtgccagcagt tggggacagggg aactatggctacaccttc 2/24 (8%)
Patient AAA06





06-01 C A S K E G L A L G E Q F F Vb22.1Db2.1Jb2.1 <0.0001 <0.0001
tgtgccagc aaggagggactagcgttagg tgagcagttcttc 24/41 (59%)
06-03 C A S S L F L A A T D H N E Q F F Vb3.1Db2.1Jb2.1 <0.0001 0.0006
tgtgccagcagt ttattcctagcggctactgacc acaatgagcagttcttc 8/41 (20%)
06-12 C A W S W T G G G Y T F Vb20.1Db1.1Jb1.2 0.0004 0.01
tgtgcctggagt tggaccggcgga ggctacaccttc 6/41 (15%)
06-06 C A S S L F L A A T D R N E Q F F Vb3.1Db2.1Jb2.1 NS NS
tgtgccagcagt ttattcctagcggctactgaccg caatgagcagttcttc 1/41 (2%)
06-07 C A S S L S R N D P Q E T Q Y F Vb6.2Db2.1Jb2.5 NS NS
tgtgccagcagc ttatccaggaatgatccc caagagacccagtacttc 1/41 (2%)
06-21 C A S E E G L A L G E Q F F Vb22.1Db2.1Jb2.1 NS NS
tgtgccagc gaggagggactagcgttagg tgagcagttcttc 1/41 (5%)
Patient AAA10





10-07 C A S S L G V S W T S G D S V S Y N Vb14.1Db2.1Jb2.1 0.06 0.19
tgtgccagcagtttg ggtgtgagctggactagcggggactcggtc tcctacaat 3/26 (11.5%)
10-31 C A S S V D P L G K T S G S T I Y F Vb1.1Db1.1Jb1.3 NS NS
tgtgccagcagcgta gacccattggggaagacc tctggaagcaccatatatttt 1/26 (3.8%)
10-13 C A S S G T S N E Q F F Vb1.1Db2.1Jb2.1 NS NS
tgtgccagcagc ggtactag caatgagcagttcttc 1/26 (3.8%)
10-16 C S A P D R N T E A F F Vb2.1Db1.1Jb1.1 NS NS
tgcagtgcc cccgacagg aacactgaagctttcttt 1/26 (3.8%)





10-09 C A S S S S P A R T G S A Y N E Q Vb3.1Db2.1Jb2.1 <0.0001 <0.0001
tgtgccagcagt tcctcacccgcgagaacaggaagcg cctacaatgagcag 10/41 (24%)
10-03 C A S T T S G G G R R P Q H F Vb3.1Db1.1Jb1.5 0.0004 0.01
tgtgccagc accacctcgggggggggcagaag gccccagcatttt 6/41 (15%)
10-02 C A S S L G P G Q R A F F Vb3.1Db1.1Jb1.1 0.19 0.28
tgtgccagcagt ttgggtccgggacg agctttcttt 2/41 (5%)
10-31 C A S T A G T Y P E A F F Vb3.1JDb1.1b1.1 0.19 0.28
tgcgccagc acagcggggacgtacc ctgaagctttcttt 2/41 (5%)
10-17 C A S S L K G T N Y G Y T F Vb3.1Db2.1Jb1.2 0.19 0.28
tgtgccagcagt ttgggaact aactatggctacaccttc 2/41 (5%)
10-13 C A S S S L E L E G T I Y F Vb3.1D2.1Jb1.3 0.19 0.28
tgtgccagcagt tccttagagctcgaggg caccatatatttt 2/41 (5%)
10-06 C A S S S S S G D Y N E Q F F Vb3.1Db2.1Jb2.1 0.19 0.28
tgtgccagcagt agttctagcggggac tacaatgagcagttcttc 2/41 (5%)
10-18 C A T A L F V Q A S S Y N E Q F F Vb3.1Db2.1Jb2.1 0.19 0.28
tgtgcc accgctctgttcgtccaggctagtag ctacaatgagcagttcttc 2/41 (5%)
10-26 C A S S L G T S G E Q F F Vb3.1D2.1Jb2.1 0.19 0.28
tgtgccagcagt ctggggactagcgg tgagcagttcttc 2/41 (5%)
10-19 C A S H S P G Q G Q E T Q Y F Vb3.1Db2.1Jb2.5 0.19 0.28
tgtgccagc cactcccccggacaggga caagagacccagtacttc 2/41 (5%)
Patient AAA12





11-01 C S A R E N G D I T P L H F Vb2.1Db1.1Jb1.6 0.19 0.28
tgcagtgctaga gagaatggagacattacc cccctccacttt 2/45 (4.4%)
11-09 C S A Y R V G A Y E Q Y F Vb2.1Db1.1Jb2.7 0.19 0.28
tgcagtgct tacagggtggggg cctacgagcagtacttc 2/45 (4.4%)
11-16 C A S S L P R D Q P Q H F Vb3.1Db1.1Jb1.5 0.19 0.28
tgtgccagcagt ctccctcggg atcagccccagcatttt 2/45 (4.4%)
11-12 C A S S E Q S N T E A F F Vb18.1Db1.1Jb1.1 0.19 0.28
tgtgccagctca gagcagtcg aacactgaagctttcttt 2/45 (4.4%)
(Table continues)

















peripheral blood CD4+ cells (Table V) and CD8+ cells (Table VI)
from a normal donor were amplified by NPA-PCR. Sequence
analysis revealed unique transcripts when compared with each
other, with the exception of one clone that appeared in dupli-
cate (Table V).
Control studies reveal that the results obtained represent true
clonal expansions of T lymphocytes
It could be argued that if TCR transcript amplification by two PCR
cycles is carried out from very few T cells, it is possible that each
pair of primers will amplify signals from only a few T cells, providing
Table II. (Continued )
Clone Vb N-Db-N Jb
Transcript Frequency
in Specimen p Value
Patient AAA04





04-21 C A S S Q V F D R V D S P L H F Vb7.2Db1.1Jb1.6 0.19 0.28
tgcgccagcagccaa gtattcgacagggtgg attcacccctccacttt 2/30 (6.67%)
04-20 C S A G T G S A T E A F F Vb2.1Db1.1Jb1.1 NS NS
tgcagtgcg gggacagggtcggc cactgaggctttcttt 1/30 (3.33%)
04-05 C A S S P L E Q G E Y N E Q F F Vb3.1Db1.1Jb2.1 NS NS
tgtgccagcagt cccttagagcagggggag tacaatgagcagttcttc 1/30 (3.33%)





04-09 C A S S L G S Y E Q Y F Vb3.1Db2.1Jb2.7 0.01 0.09
tgtgccagcagc ctgggc tcctacgagcagtacttc 4/22 (18%)
04-01 C A S S L L G G S S Y N E Q F F Vb3.1Db2.1Jb2.1 0.19 0.28
tgtgccagcagt ttactcggcgggagc tcctacaatgagcagttcttc 2/22 (9%)
Patient AAA02





02-32 C A S R S S G K S S Y N E Q F F Vb3.1Db2.1Jb2.1 0.19 0.29
tgtgccagc aggagtagcggaaagagc tcctacaatgagcagttcttc 2/20 (10.0%)
02-14 C A S S V A G R G N T E A F F Vb1.1Db1.1Jb1.1 NS NS
tgtgccagcagcgta gcgggcagaggg aacactgaagctttcttt 1/20 (5.0%)
02-11 C S A R D Y S T A N M N T E A F F Vb2.1Db1.1Jb1.1 NS NS
tgcagtgctaga gattattccaccgcaaacatg aacactgaagctttcttt 1/20 (5.0%)
02-52 C A S S Q G S G N N E K L F F Vb9.1Db2.1Jb1.4 NS NS
tgtgccagcagc caaggttccgggaat aatgaaaaactgtttttt 1/20 (50%)
Patient AAA07





07-26 C A S S A T G T F P D T Q Y F Vb1.1Db1.1Jb2.3 NS NS
tgtgccagcagc gctaccgggacattcc cagatacgcagtatttt 1/21 (4.8%)
07-04 C S A R G Q R F Y E Q Y F Vb2.1Db1.1Jb2.7 NS NS
tgcagtgctaga ggacagcgtttt tacgagcagtacttc 1/21 (4.8%)
07-15 C A S S L G W V A K D E K L F F Vb5.1Db1.1Jb1.4 NS NS
tgcgccagcagcttg ggttgggtggccaaggac gaaaaactgtttttt 1/21 (4.8%)
07-14 C A S S P G T D L S P L H F Vb5.1Db1.1Jb1.6 NS NS
tgcgccagcagt ccagggacggatct ttcacccctccacttt 1/21 (4.8%)





07-04 C A S S P V G Q S T D T Q Y F Vb6.3Db2.1Jb2.3 0.01 0.09
tgtgccagcagc ccagttgggcag agcacagatacgcagtatttt 4/19 (21%)
07-05 C A S S L V L V G N E Q F F Vb6.2Db2.1Jb2.1 0.06 0.19
tgtgccagcagc ttagttctagtaggt aatgagcagttcttc 3/19 (16%)
07-07 C A S S P E D L S T D T Q Y F Vb6.3Db2.1Jb2.3 0.19 0.29
tgtgccagcagc cccgaagacctt agcacagatacgcagtatttt 2/19 (11%)
07-01 C A S S L V L R Q G G F Y E Q Y F Vb6.2Db1.1Jb2.7 0.19 0.29
tgtgccagcagc ttagtcctgcgacaggggggttt ctacgagcagtacttc 2/19 (11%)
07-14 C A S S S G G G Q G A L G F Y N E Vb6.3Db1.1Jb2.1 0.19 0.29
tgtgccagcagc tcgggggggggacagggggcgctcggatt ctacaatgag 2/19 (11%)
07-16 C A S S L T D A S S G N T I Y F Vb6.3Db2.1Jb1.3 0.19 0.29
tgtgccagcagc ttaacggacgccagc tctggaaacaccatatatttt 2/19 (11%)
aThe remaining 24 sequences are unique when compared with each other and are not listed here.
bThe remaining 9 sequences are unique when compared with each other and are not listed here.
cThe remaining 13 sequences are unique when compared with each other and are not listed here.
dThe remaining 17 sequences are unique when compared with each other and are not listed here.
eThe remaining 12 sequences are unique when compared with each other and are not listed here.
fThe remaining 7 sequences are unique when compared with each other and are not listed here.
gThe remaining 12 sequences are unique when compared with each other and are not listed here.
hThe remaining 20 sequences are unique when compared with each other and are not listed here.
iThe remaining 9 sequences are unique when compared with each other and are not listed here.
jThe remaining 37 sequences are unique when compared with each other and are not listed here.
kThe remaining 26 sequences are unique when compared with each other and are not listed here.
lThe remaining 16 sequences are unique when compared with each other and are not listed here.
mThe remaining 15 sequences are unique when compared with each other and are not listed here.
nThe remaining 17 sequences are unique when compared with each other and are not listed here.

















results that may resemble those in Table II. We demonstrated that this
is not the case; our results represent true clonal expansions of T cells
and are not due to amplification of TCR transcripts from just a few
T cells.
First, each aorta biopsy from patients with AAAwas divided into
two fractions; one was used for histology and immunohistochem-
istry, and the other was used for RNA preparation. RNAwas isolated
with a yield of ∼10 mg/preparation, which represents ∼1.0 3 107
cells. From this RNA we used 50 ng for PCR amplification, which
represents ∼5.0 3 104 cells. It should be emphasized that the
representation of the TCR clonotypes does not change between
the sample of 10 mg of RNA and the sample of 50 ng that we
used for PCR amplification, cloning, and sequencing. The TCR
clonotypes, particularly the expanded ones present in 10 mg of
RNA, are also present in the 50 ng of RNA. The ratio of the
various TCR clonotypes to each other does not change. What
does change when different amounts of RNA are used is the ab-
solute number of the TCR copies present. Second, we determined
the number of T cells present in aorta specimens used for RNA
preparations from two patients with AAA (AAA09 and AAA10)
by immunohistochemical staining using an anti-CD3 mAb. The
number of CD3+ T cells varies significantly, ranging from 0 to
155 for each high-power field. Twenty high-power fields were
counted in each specimen by two persons independently. The
average number of CD3+ T cells was ∼780/section in specimen
AAA09 and ∼660/section in specimen AAA10. Given the thickness
of aorta biopsy specimens of ∼5 mm and that the cryostat sections
of aorta biopsies used for the immunohistochemical determi-
nations were 6-mm-thick each, the total number of CD3+ T cells
used for RNA isolation in specimens AAA09 and AAA10 was
estimated to be 6.53 105 and 5.53 105, respectively. Because 10 mg
of RNA (representing ∼13 107 cells) was recovered per preparation,
CD3+ T cells in these specimens accounted for 6.5 and 5.5%, re-
spectively (mean 6.0%), of the total cells used for RNA isolation.
Fifty nanograms of RNA (representing ∼5 3 104 cells) was used for
PCR amplification. Approximately 6.0% of these cells (i.e., ∼3000
cells) were CD3+ T lymphocytes in these amplification reactions.
Control experiments were conducted to detect the threshold of
starting T cell numbers that will give polyclonal sequencing results
after two PCR cycles. Sequence analysis, after NPA-PCR ampli-
fication and cloning with various amounts of template, revealed the
presence of unique transcripts when compared with each other,
with the exception of two doublets (not statistically significant),
which is typical of polyclonal T cells, when the starting T cell
number was as low as 300 (data not shown). These cells were
10 times lower than those present in AAA specimens used in the
experiments reported in this study (i.e., 3000 T cells).
A similar strategy was used for Vb-specific amplification, fol-
lowed by cloning and sequencing (data not shown). Sequence
analysis, from the mixture that contained as few as 1200 T cells,
corresponding to 100 Vb2+ T cells in 50 ng of RNA, revealed the
presence of unique Vb2+ TCR transcripts when compared with
each other, with the exception of two doublets (not statistically
significant), which is typical of polyclonal populations of T cells.
The T cell number (1200) was lower than that present (3000 cells)
in 50 ng of RNA from AAA specimens. From the mixture, which
contained only 300 T cells or 24 Vb2+ T cells, a more restricted
pattern was observed (not statistically significant), consisting of
one Vb2+ transcript that appeared in triplet, four transcripts that
appeared in doublets, and eight other transcripts that appeared as
a single copy (data not shown). These results confirmed that the
clonality of T cells in AAA lesions was due to real clonal ex-
pansions and not to amplifications of TCR transcripts from just
a few T cells.
DNA-based HLA typing for HLA-DRB1, HLA-DQA1, and
HLA-DQB1
Six of 10 patients with AAA were typed by DNA-based HLA
typing for HLA-DRB1, HLA-DQA1, and HLA-DQB1 (Table VII).
Five of these six patients—AAA02, AAA03, AAA04, AAA09,
and AAA10—expressed DRB1 alleles positive for the DRbGln70
amino acid residue (Table VII), which was reported to be asso-
ciated with AAA (13). Clonally expanded T cells in AAA lesions
were found in five (AAA03, AAA04, AAA06, AAA09, and AAA10)
of these six patients (Table II). These included four patients who
expressed DRbGln70 (AAA03, AAA04, AAA09, and AAA10)
and one who did not (AAA06) (Table VII).
Conserved CDR3 amino acid motifs
In addition to clonally expanded TCR transcripts, several con-
served CDR3 amino acid motifs (GA, GL, LA, SG, and SR) were
expressed in statistically significantly higher proportions in CDR3s
of patients with AAA than in CDR3s of PBMCs from healthy
donors (Table VIII). Sequences from 333 b-chain TCR transcripts
from PBMCs of seven healthy donors (this study and 32–36) were
used as normal controls.
Table III. b-chain TCR transcripts (CDR3 region) expressed in purified CD4+ and CD8+ T cells from AAA lesions of patient AAA14
Clone Vb N-Db-N Jb
Transcript Frequency
in Specimen p Value





14-02 C S A R D L A G N E Q F F Vb2.1Db2.1Jb2.1 <0.0001 0.0015
tgcagtgct agagatctagcgggg aatgagcagttcttc 7/15 (47%)
14-01 C A S S P K T G I S Y E Q Y F Vb18.1Db1.1Jb2.7 0.002 0.03
tgtgccagctca cccaagacagggatc tcctacgagcagtacttc 5/15 (33%)
14-06 C A S S T T D G S Y E Q Y F Vb1.1DbJb2.7 0.19 0.29
tgtgccagcagc accacggacggg tcctacgagcagtacttc 2/15 (13%)
14-09 C A S S Q G R R Y E Q Y F Vb16.1DbJb2.7 NS NS
tgtgccagcagc caaggtaggagg tacgagcagtacttc 1/15 (7%)





14-13 C A S S P Y G G A T G E L F F Vb18.1Db2.1Jb2.2 0.06 0.19
tgtgccagctca ccgtacgggggggc caccggggagctgtttttt 3/14 (21%)
14-99 C S A S L D S W T Q E T Q Y F Vb2.1Db1.1Jb2.4 0.06 0.19
tgcagtgct agcctcgatagttggacccaagagacc cagtacttc 3/14 (21%)
aThe remaining eight sequences are unique when compared with each other and are not listed here.

















Table IV. b-chain TCR transcripts (CDR3 region) expressed in PBMCs from a healthy donor
Clone Vb N-Db-N Jb
Transcript Frequency
in Specimen p Value p Value





NBBnpa078 C A S S V G M G D T E A F F Vb1.1Db1.1Jb1.1 NS NS
tgtgccagcagc gtaggtatggggg acactgaagctttcttt 1/67
NBBnpa029 C A S S A W G T Y N E Q F F Vb1.1Db1.1Jb2.1 NS NS
tgtgccagcagc gcctggggca cctacaatgagcagttcttc 1/67
NBBnpa120 C S A P R Q G A G N T E A F F Vb2.1Db1.1Jb1.1 NS NS
tgcagtgct ccaagacagggggccggg aacactgaagctttcttt 1/67
NBBnpa079 C S A R D M R Q G P S N E K L F F Vb2.1Db1.1Jb1.4 NS NS
tgcagtgctaga gatatgagacagggaccat ctaatgaaaaactgtttttt 1/67
NBBnpa101 C S A K V Q G G N Q P Q H F Vb2.1Db1.1Jb1.5 NS NS
tgcagtgct aaggtccagggcgga aatcagccccagcatttt 1/67
NBBnpa012 C S A R G Q E D Q P Q H F Vb2.1Db1.1Jb1.5 NS NS
tgcagtgctaga gggcaggagg atcagccccagcatttt 1/67
NBBnpa061 C S A R G L A G H L R D N E Q F F Vb2.1Db2.1Jb2.1 NS NS
tgcagtgctaga ggactagcgggccatctacgcg acaatgagcagttcttc 1/67
NBBnpa068 C S A R T G A N E Q F F Vb2.1Db1.1Jb2.1 NS NS
tgcagtgccagg acaggggc caatgagcagttcttc 1/67
NBBnpa083 C S A V Q W G E S D T Q Y F Vb2.1Db1.1Jb2.3 NS NS
tgcagtgcc gtccagtggggagaat cagatacgcagtatttt 1/67
NBBnpa063 C S A P G P D L A K N I Q Y F Vb2.1Db2.1Jb2.4 NS NS
tgcagtgct cccgggcctgattta gccaaaaacattcagtacttc 1/67
NBBnpa072 C S A S G G N D G E E T Q Y F Vb2.1Db1.1Jb2.5 NS NS
tgcagtgct agcgggggaaatgatgggg aagagacccagtacttc 1/67
NBBnpa106 C A S S L Y H Y R G G G F N E Q F Vb3.1Db1.1Jb2.1 NS NS
tgtgccagcagt ttatatcactacaggggaggtgggtt caatgagcagttc 1/67
NBBnpa107 C A S S L L D D L S G E Q Y F Vb3.1Db2.1Jb2.7 NS NS
tgtgccagcagt ttattggacgatctgtcggg cgagcagtacttc 1/67
NBBnpa108 C S G A G T A L E T Q Y F Vb4.1Db1.1Jb2.5 NS NS
tgcagc ggggcggggacagctttg gagacccagtacttc 1/67
NBBnpa036 C S V G I N G R E Q Y F Vb4.1Db1.1Jb2.7 NS NS
tgcagcgtt gggattaatggacg cgagcagtacttc 1/67
NBBnpa010 C S V T D R P A G E Q Y F Vb4.1Db1.1Jb2.7 NS NS
tgcagcgtt acggacaggcccgccgg cgagcagtacttc 1/67
NBBnpa040 C A S S P R Q G L N T E A F F Vb5.1Db1.1Jb1.1 NS NS
tgcgccagcagc ccccgacagggtctg aacactgaagctttcttt 1/67
NBBnpa126 C A S S L S R A G E K L F F Vb5.1Db1.1Jb1.4 NS NS
tgcgccagcagc ttgtccagggcggg tgaaaaactgtttttt 1/67
NBBnpa013 C A S S G R T G V A A E Q Y F Vb5.1Db1.1Jb2.7 NS NS
tgcgccagcagc ggtcggacaggcgtagcggc cgagcagtacttc 1/67
NBBnpa118 C A S S P R G R G R L T Y N E Q F Vb5.2Db2.1Jb2.1 NS NS
tgtgccagcagc ccccgaggccgcggccgactga cctacaatgagcagttc 1/67
NBBnpa127 C A S S H A D L G G R G Y N E Q F Vb6.1Db1.1Jb2.1 NS NS
tgtgccagcagc catgctgaccttggcgggagggga tacaatgagcagttc 1/67
NBBnpa046 C A S S S T A N E Q F F Vb6.2Db1.1Jb2.1 NS NS
tgtgccagcagc tctacggcg aatgagcagttcttc 1/67
NBBnpa009 C A S S L E G L N E Q Y F Vb6.2Db1.1Jb2.7 NS NS
tgtgccagcagc ttagaggggttaa acgagcagtacttc 1/67
NBBnpa004 C A S S L V N Q P Q H F Vb6.3Db1.1Jb1.5 NS NS
tgtgccagcagc ttagtt aatcagccccagcatttt 1/67
NBBnpa042 C A S S T P E G V H G Y T F Vb6.4Db1.1Jb1.2 NS NS
tgtgccagcagc accccagagggggttc atggctacaccttc 1/67
NBBnpa015 C A S S L I L S G N T I Y F Vb6.4Db2.1Jb1.3 NS NS
tgtgccagcagc ttaatcctc tctggaaacaccatatatttt 1/67
NBBnpa111 C A S S L G L A G V S E Q Y F Vb6.5Db2.1Jb2.7 NS NS
tgtgccagcagc ttaggactagcgggagtctc cgagcagtacttc 1/67
NBBnpa116 C A S S Q E V R A E R R D T Q Y F Vb7.1Db2.1Jb2.3 NS NS
tgcgccagcagc caagaagttcgagcggagaggcgg gatacgcagtatttt 1/67
NBBnpa035 C A S S Q G R T G R G S E Q Y F Vb7.1Db1.1Jb2.7 NS NS
tgcgccagcagc caaggccgtacagggcgagggtc cgagcagtacttc 1/67
NBBnpa080 C A S S P T A T G E L F F Vb8.2Db2.1Jb2.2 NS NS
tgtgccagcagc ccgactgc caccggggagctgtttttt 1/67
NBBnpa018 C A S S L G G P G P D T Q Y F Vb8.2Db1.1Jb2.3 NS NS
tgtgccagcagt ttgggagggcccggtc cagatacgcagtatttt 1/67
NBBnpa020 C A S S L G R R Q P Q H F Vb9.1Db2.1Jb1.5 NS NS
tgtgccagcagc ctcgggaggagg cagccccagcatttt 1/67
NBBnpa007 C V A F T I G E T E A F F Vb13.1Db2.1Jb1.1 NS NS
tgt gtcgcctttactatcggggaa actgaagctttcttt 1/67
NBBnpa067 C A S S L Y N E Q F F Vb13.1Db2.1Jb2.1 NS NS
tgtgccagcagt tta tacaatgagcagttcttc 1/67
NBBnpa130 C A S S Y G S F S D T Q Y F Vb13.1Db2.1Jb2.3 NS NS
tgtgccagcagt tacggcagcttct cagatacgcagtatttt 1/67
(Table continues)

















Table IV. (Continued )
Clone Vb N-Db-N Jb
Transcript Frequency
in Specimen p Value p Value
NBBnpa002 C A S S L P G E A F F Vb13.2Db1.1Jb1.1 NS NS
tgtgccagcagc ttaccaggg gaagctttcttt 1/67
NBBnpa014 C A S S Y L Q G N T Q Y F Vb13.2Db1.1Jb2.3 NS NS
tgtgccagcagt tacctacagggaa atacgcagtatttt 1/67
NBBnpa039 C A S S A G P G Q V N T E A F F Vb13.6Db1.1Jb1.1 NS NS
tgtgccagcagt gctgggccgggacaggtg aacactgaagctttcttt 1/67
NBBnpa059 C A S S Y G P R E Q Y F Vb13.6Db2.1Jb2.7 NS NS
tgtgccagcagt tacggccctcgt gagcagtacttc 1/67
NBBnpa066 C A S S S R T A N T E A F F Vb14.1Db1.1Jb1.1 NS NS
tgtgccagcagc tcccggacagcg aacactgaagctttcttt 1/67
NBBnpa076 C A S S F Q K I S G L G N E Q F F Vb14.1Db2.1Jb2.1 NS NS
tgtgccagcagt tttcaaaagattagcgggttagg caatgagcagttcttc 1/67
NBBnpa104 C A S R S P G R T D T Q Y F Vb14.1Db2.1Jb2.3 NS NS
tgtgccagc aggagtcctggtagg acagatacgcagtatttt 1/67
NBBnpa102 C A S S S A N Y N D R L A K N I Q Vb14.1Db1.1Jb2.4 NS NS
tgtgccagcagt tccgccaattataatgacagacta gccaaaaacattcag 1/67
NBBnpa041 C A S S V V S Q E T Q Y F Vb14.1Db1.1Jb2.5 NS NS
tgtgccagcagt gtggtcagc caagagacccagtacttc 1/67
NBBnpa054 C A S S L S S Y G G E T Q Y F Vb14.1Db2.1Jb2.5 NS NS
tgtgccagcagt ttatcgagttatggcgg agagacccagtacttc 1/67
NBBnpa052 C A T D F S A G G E Q Y F Vb15.1Db2.1Jb2.7 NS NS
tgtgcc acggattttagcgctggagg cgagcagtacttc 1/67
NBBnpa069 C A S S P G L N Y G Y T F Vb16.1Db2.1Jb1.2 NS NS
tgtgccagcagc cccggactg aactatggctacaccttc 1/67
NBBnpa060 C A S S Q G L N E Q Y F Vb16.1Db2.1Jb2.7 NS NS
tgtgccagcagc caaggtctga acgagcagtacttc 1/67
NBBnpa008 C A S S P R T P R T V A F F Vb17.1Db1.1Jb1.1 NS NS
tgtgccagtagt ccccggacccccagaacggtg gctttcttt 1/67
NBBnpa001 C A S S P K A T E A F F Vb18.1Db1.1Jb1.1 NS NS
tgtgccagctca ccaaaggct actgaagctttcttt 1/67
NBBnpa123 C A S S P G Q A L Y G Y T F Vb18.1Db1.1Jb1.2 NS NS
tgtgccagctca ccgggacaggcgtta tatggctacaccttc 1/67
NBBnpa073 C A S S P P L P G I N E Q F F Vb18.1Db2.1Jb2.1 NS NS
tgtgccagctca ccacctcttccgggtat caatgagcagttcttc 1/67
NBBnpa112 C A S R A R R Y N E Q F F Vb18.1Db1.1Jb2.1 NS NS
tgtgccagc cgggccaggcga tacaatgagcagttcttc 1/67
NBBnpa071 C A W S V Q G G V G N Q P Q H F Vb20.1Db1.1Jb1.5 NS NS
tgtgcctggagt gtgcagggtggggtcg gcaatcagccccagcatttt 1/67
NBBnpa115 C A W S N N R G G R I R Y N E Q F Vb20.1Db1.1Jb2.1 NS NS
tgtgcctggagc aataaccgagggggtaggataagg tacaatgagcagttc 1/67
NBBnpa109 C A W S T G S K Y E Q Y F Vb20.1Db1.1Jb2.7 NS NS
tgtgcctggagt acagggtctaaa tacgagcagtacttc 1/67
NBBnpa026 C A S S L A L G R E L G E Q F F Vb21.3Db2.1Jb2.1 NS NS
tgtgccagcagc ttagctctagggcgggagctagg tgagcagttcttc 1/67
NBBnpa064 C A S S L G R G R G T E Q F F Vb21.3Db2.1Jb2.1 NS NS
tgtgccagcagc ttagggcgcgggagggggac tgagcagttcttc 1/67
NBBnpa058 C A S S D T G T S R E Q Y F Vb21.3Db2.1Jb2.7 NS NS
tgtgccagcagc gacaccgggactagccgt gagcagtacttc 1/67
NBBnpa125 C A S S L D R G S V Q Y F Vb21.3Db2.1Jb2.7 NS NS
tgtgccagcagc ttagatcggggctcggt gcagtacttc 1/67
NBBnpa038 C A S S A D T G S Q P Q H F Vb22.1Db1.1Jb1.5 NS NS
tgtgccagcagt gcggacaccgggtc tcagccccagcatttt 1/67
NBBnpa074 C A S S P G A S G G Q P Q H F Vb22.1Db2.1Jb1.5 NS NS
tgtgccagt tcccccggggcgtcgggggg tcagccccagcatttt 1/67
NBBnpa119 C A S S E I V W G D E Q F F Vb22.1Db1.1Jb2.1 NS NS
tgtgccagcagt gaaattgtatggggtg atgagcagttcttc 1/67
NBBnpa065 C A S S G Q S G T E E Q F F Vb22.1Db1.1Jb2.1 NS NS
tgtgccagc tccggacagtccgggaccgag gagcagttcttc 1/67
NBBnpa005 C A S S R W P D T Q Y F Vb22.1Db1.1Jb2.3 NS NS
tgtgccagcagt cgatggc cagatacgcagtatttt 1/67
NBBnpa053 C A S S Q S S F G A N V L T F Vb22.1Db2.1Jb2.6 NS NS
tgtgccagcagt caatctagctt tggggccaacgtcctgactttc 1/67
NBBnpa055 C A S S L Y P N S P L H F Vb23.1Db2.1Jb1.6 NS NS
tgtgccagcagc ttatacccg aattcacccctccacttt 1/67





NBBvb0234 C S A T G T G A I Q Y F Vb2.1Db1.1Jb2.4 0.19 0.28
tgcagtgct accgggacaggagc cattcagtacttc 2/37 (5%)
NBBvb0240 C S A L G Q N T E A F F Vb2.1Db1.1Jb1.1 NS NS
tgcagtgct ttaggacag aacactgaagctttcttt 1/37 (3%)
(Table continues)

















Table IV. (Continued )
Clone Vb N-Db-N Jb
Transcript Frequency
in Specimen p Value p Value
NBBvb0219 C S A R D A G R M N T E A F F Vb2.1Db1.1Jb1.1 NS NS
tgcagtgctaga gacgccgggcggatg aacactgaagctttcttt 1/37 (3%)
NBBvb0246 C S A R D H G L G Y T F Vb2.1Db1.1Jb1.2 NS NS
tgcagtgctaga gatcacgggcta ggctacaccttc 1/37 (3%)
NBBvb0201 C S A P D S R Y G Y T F Vb2.1Db1.1Jb1.2 NS NS
tgcagtgca ccagacagtcg ctatggctacaccttc 1/37 (3%)
NBBvb0203 C S A G D R D Y G Y T F Vb2.1Db1.1Jb1.2 NS NS
tgcagtgcc ggggacaggg actatggctacaccttc 1/37 (3%)
NBBvb0213 C S A E D R R I S R Y T F Vb2.1Db1.1Jb1.2 NS NS
tgcagtgct gaggacagaaggatctcgc gctacaccttc 1/37 (3%) 1
NBBvb0227 C S A R N P G H R N Y G Y T F Vb2.1Db1.1Jb1.2 NS NS
tgcagtgct cgtaacccgggacacaga aactatggctacaccttc 1/37 (3%)
NBBvb0228 C S A S R T G V G G Y T F Vb2.1Db1.1Jb1.2 NS NS
tgcagtgct agcaggacaggggtcggg ggctacaccttc 1/37 (3%)
NBBvb0214 C S A R P G S G N T I Y F Vb2.1Db1.1Jb1.3 NS NS
tgcagtgctaga ccgggc tctggaaacaccatatatttt 1/37 (3%)
NBBvb0252 C S A R S P G T G G G E K L F F Vb2.1Db1.1Jb1.4 NS NS
tgcagtgctaga agtcccgggacagggggcgg tgaaaaactgtttttt 1/37 (3%)
NBBvb0241 C S A R E A G L N Q P Q H F Vb2.1Db1.1Jb1.5 NS NS
tgcagtgctaga gaggcaggtct caatcagccccagcatttt 1/37 (3%)
NBBvb0248 C S V N L Q G G N N Q P Q H F Vb2.1Db1.1Jb1.5 NS NS
tgcagt gttaacctccagggggggaa caatcagccccagcatttt 1/37 (3%)
NBBvb0202 C S A Q S P R S N Q P Q H F Vb2.1Db1.1Jb1.5 NS NS
tgcagtgcc caaagcccccgctc caatcagccccagcatttt 1/37 (3%)
NBBvb0222 C S A R D T N R M G N Q P Q H F Vb2.1Db1.1Jb1.5 NS NS
tgcagtgcc agggacacgaataggatgg gcaatcagccccagcatttt 1/37 (3%)
NBBvb0236 C S A R G L A G H L R D N E Q F F Vb2.1Db2.1Jb2.1 NS NS
tgcagtgctaga ggactagcgggccatctacgcg acaatgagcagttcttc 1/37 (3%)
NBBvb0251 C S A R G L A G H L L D N E Q F F Vb2.1Db2.1Jb2.1 NS NS
tgcagtgctaga ggactagcgggccatctactcg acaatgagcagttcttc 1/37 (3%)
NBBvb0206 C S A I P S G R I S N E Q F F Vb2.1Db2.1Jb2.1 NS NS
tgcagtgcg atcccgagcgggagaattag caatgagcagttcttc 1/37 (3%)
NBBvb0224 C S A R R G G R S G E T Q F F Vb2.1Db2.1Jb2.1 NS NS
tgcagtgct cgccggggagggcggagtggagagacc cagttcttc 1/37 (3%)
NBBvb0212 C S A S P R S N T G E L F F Vb2.1Db2.1Jb2.2 NS NS
tgcagtgcc agccctagatcg aacaccggggagctgtttttt 1/37 (3%)
NBBvb0225 C S A R L P N T G E L F F Vb2.1Db2.1Jb2.2 NS NS
tgcagtgcg aggcttcca aacaccggggagctgtttttt 1/37 (3%)
NBBvb0243 C S A R F N Y G E L F F Vb2.1Db2.1Jb2.2 NS NS
tgcagtgctaga tttaatta cggggagctgtttttt 1/37 (3%)
NBBvb0245 C S A R R T G G N T G E L F F Vb2.1Db1.1Jb2.2 NS NS
tgcagtgctaga cggacaggaggg aacaccggggagctgtttttt 1/37 (3%)
NBBvb0232 C S A R D R E A D T Q Y F Vb2.1Db2.1Jb2.3 NS NS
tgcagtgctaga gatcgggagg cagatactcagtatttt 1/37 (3%)
NBBvb0253 C S A T G G D S V A Y T Q Y F Vb2.1Db1.1Jb2.3 NS NS
tgcagtgcc accgggggggacagcgtagcat atacgcagtatttt 1/37 (3%)
NBBvb0226 C S A T S T S G S T D T Q Y F Vb2.1Db2.1Jb2.3 NS NS
tgcagtgct acgtctactagcggg agcacagatacgcagtatttt 1/37 (3%)
NBBvb0204 C S P R G G G S D T Q Y F Vb2.1Db2.1Jb2.3 NS NS
tgcagt cccagggggggaggaagc gatacgcagtatttt 1/37 (3%)
NBBvb0209 C S A R D L R D K D T Q Y F Vb2.1Db2.1Jb2.3 NS NS
tgcagtgctaga gatttgcgggacaa agatacgcagtatttt 1/37 (3%)
NBBvb0210 C S A T E L A G A S K N I Q Y F Vb2.1Db2.1Jb2.4 NS NS
tgcagtgct accgaactagcgggagcatc caaaaacattcagtacttc 1/37 (3%)
NBBvb0233 C S A S R A Q E T H Y F Vb2.1Db2.1Jb2.5 NS NS
tgcagtgct agccgggcc caagagacccattacttc 1/37 (3%)
NBBvb0238 C S A R A R A G F P T E T Q Y F Vb2.1Db2.1Jb2.5 NS NS
tgcagtgctaga gcgcgggcaggcttcccatg ggagacccagtacttc 1/37 (3%)
NBBvb0254 C S A R E T L D Q E T Q Y F Vb2.1Db2.1Jb2.5 NS NS
tgcagtgctaga gaaactttggac caagagacccagtacttc 1/37 (3%)
NBBvb0208 C S A R R G G R S G E T Q Y F Vb2.1Db2.1Jb2.5 NS NS
tgcagtgct cgccggggagggcggagtgg agagacccagtacttc 1/37 (3%)
NBBvb0231 C S A R D R K Q T L S Y Q Q Y F Vb2.1Db2.1Jb2.7 NS NS
tgcagtgctaga gatagaaagcagaccctc tcctaccagcagtacttc 1/37 (3%)
NBBvb0242 C S A R S L R E P Y E Q Y F Vb2.1Db1.1Jb2.7 NS NS
tgcagtgctagg tccctcagggaacc ctacgagcagtacttc 1/37 (3%)
NBBvb0249 C S A T D M R D T G S H S Y E Q Vb2.1Db1.1Jb2.7 NS NS
tgcagtgct accgacatgagggacaccgggtcccac tcctacgagcag 1/37 (3%)

















Comparison of the nucleic acid and deduced amino acid
sequences with those in the GenBank/European Molecular
Biology Laboratory database
Comparison of all sequences obtained in this study with those in the
GenBank/European Molecular Biology Laboratory database using
BLAST software revealed that they are novel. There were no cases
of identical b-chain TCR transcripts appearing in different AAA
patients. However, analysis of the CDR3 motifs in the clonally
expanded sequences, using the gapped BLAST and PSI-BLAST
protein database search programs, revealed substantial homologies
between the b-chain TCR transcripts in AAA patients and those in
the GenBank/European Molecular Biology Laboratory database.
Table V. b-chain TCR transcripts (CDR3 region) expressed in purified CD4+ T cells from PBMCs of a healthy donor
Clone Vb N-Db-N Jb
Transcript Frequency in
Specimen; p value
b-chain TCR transcripts amplified by NPA-PCR
NBCD405 C A S R T N N L G E L F F Vb6.4Db1.1Jb1.4
tgtgccagc aggacaaataatcttgggg aactgtttttt 2/32 (7%), p = 0.19
NBCD475 C A S R A N T E A F F Vb1.1Db2.1Jb1.1
tgtgccagc agggcg aacactgaagctttcttt 1/32, NS
NBCD476 C A S S G D R E D Q P Q H F Vb1.1Db1.1Jb1.5
tgtgccagcagc ggggacagggaag atcagccccagcatttt 1/32, NS
NBCD437 C A G S A R T G E L F F Vb1.1Db1.1Jb2.2
tgtgccggcagc gccaga accggggagctgtttttt 1/32, NS
NBCD449 C S A R A T G F G T E A F F Vb2.1Db1.1Jb1.1
tgcagtgctagg gccacagggttcggg actgaagctttcttt 1/32, NS
NBCD425 C S A R S V G W D G Y T F Vb2.1Db1.1Jb1.2
tgcagtgctaga agtgtagggtggg atggctacaccttc 1/32, NS
NBCD462 C S A R R D A G N T I Y F Vb2.1Db2.1Jb1.3
tgcagtgctaga cgggacgcg ggaaacaccatatatttt 1/32, NS
NBCD432 C S A R S P G T G G G E K L F F Vb2.1Db1.1Jb1.4
tgcagtgctaga agtcccgggacagggggcgg tgaaaaactgtttttt 1/32, NS
NBCD448 C S A R G G P G H L G W E Q Y F Vb2.1Db2.1Jb2.7
tgcagtgctaga gggggaccgggacacctcgggtgg gagcagtacttc 1/32, NS
NBCD428 C A S S L F A G G S G E T Q Y F Vb3.1Db2.1Jb2.5
tgtgccagcagt ttattcgcgggaggtagtggg gagacccagtacttc 1/32, NS
NBCD419 C A S S P Y A E Q E T Q Y F Vb3.1Db2.1Jb2.5
tgtgccagcagt ccctatgcggaa caagagacccagtacttc 1/32, NS
NBCD409 C S V G I N G R E Q Y F Vb4.1Db2.1Jb2.7
tgcagcgtt gggattaatggacg cgagcagtacttc 1/32, NS
NBCD422 C A S S G R T G V A A E Q Y F Vb5.1Db1.1Jb2.7
tgcgccagcagc ggtcggacaggcgtagcggc cgagcagtacttc 1/32, NS
NBCD424 C A S S W G T G P Y E Q Y F Vb5.2Db1.1Jb2.7
tgtgccagcagc tgggggacaggacc ctacgagcagtacttc 1/32, NS
NBCD435 C A S S L E P G I T D T Q Y F Vb5.4Db2.1Jb2.3
tgtgccagcagc ttggaaccgggaat cacagatacgcagtatttt 1/32, NS
NBCD434 C A S S L G G P G P D T Q Y F Vb8.1Db2.1Jb2.3
tgtgccagcagt ttgggagggcccggtc cagatacgcagtatttt 1/32, NS
NBCD479 C A S S P A G P R A G Y T F Vb8.2Db2.1Jb1.2
tgtgccagcagt cccgccgggcccagggcc ggctacaccttc 1/32, NS
NBCD415 C A S S R A G S Y E Q Y F Vb8.2Db1.1Jb2.7
tgtgccagcagt agagcagggag ctacgagcagtacttc 1/32, NS
NBCD445 C A T Y H S Y N S P L H F Vb13.1Db1.1Jb1.6
tgtgcc acctatcac tcctataattcacccctccacttt 1/32, NS
NBCD407 C A S V D D P K P Y E Q Y F Vb13.2Db1.1Jb2.7
tgtgccagc gtagacgacccaaaacct tacgagcagtacttc 1/32, NS
NBCD481 C A S S Y R R A N S P L H F Vb13.6Db2.1Jb1.6
tgtgccagcagt taccggagggcg aattcacccctccacttt 1/32, NS
NBCD471 C A S S Y G E G E F T L H F Vb13.6Db2.1Jb1.6
tgtgccagcagt tacggggagggcg aattcaccctccacttt 1/32, NS
NBCD473 C A V L R D R W E T Q Y F Vb13.6Db1.1Jb2.5
tgtgcc gtcctccgggacaggtgg gagacccagtacttc 1/32, NS
NBCD412 C A S S Q I A G N T G E L F F Vb16.1Db2.1Jb2.2
tgtgccagcagc caaatagcgggg aacaccggggagctgtttttt 1/32, NS
NBCD414 C A S S I G P Y G Y T F Vb17.1Db1.1Jb1.2
tgtgccagtagt atcggcccg tatggctacaccttc 1/32, NS
NBCD460 C A S S P I G A D N S P L H F Vb18.1Db2.1Jb1.6
tgtgccagctca ccaattggggcag ataattcacccctccacttt 1/32, NS
NBCD452 C A S S P K T G I S Y E Q Y F Vb18.1Db1.1Jb2.7
tgtgccagctca cccaagacagggatc tcctacgagcagtacttc 1/32, NS
NBCD439 C A S S L G G L A G G N E Q F F Vb21.3Db2.1Jb2.1
tgtgccagcagc ttaggaggactagcgggagg caatgagcagttcttc 1/32, NS
NBCD485 C A S S P V Q G G F G Y T F Vb22.1Db2.1Jb1.2
tgtgccagcagt ccagtacaggggggctt tggctacaccttc 1/32, NS
NBCD463 C A S S E A S G T V Y G Y T F Vb22.1Db2.1Jb1.2
tgtgccagcagt gaagcgtcagggacggt ctatggctacaccttc 1/32, NS
NBCD489 C A T R R T S A A T D T Q Y F Vb24.1Db2.1Jb2.3
tgtgccacc aggagaactagcgccgc cacagatacgcagtatttt 1/32, NS

















The clonally expanded clone 09-02 (CDR3:CASSLLASGATDT-
QYF) from patient AAA09 shared similar CDR3 sequences with
an alloreactive human T cell clone (GenBank GI no. 930056;
CDR3:CASSFLAAGVADTQYF) and a human T cell clone of un-
known specificity (GenBank GI no. 16566875; CDR3:CASSE-
VASGTDTQYF). Clone 09-25 (CDR3:CASTPLAAGSGNTIYF)
exhibited substantial CDR3 homology to a T cell clone (GenBank
GI no. 3859306; CDR3:CASRGGQGASYEQYF) derived from
synovial fluid from patients with rheumatoid arthritis (RA). Clone
02-32 (CDR3:CASRSSGKSSYNEQFF) from patient AAA02 was
homologous to a human T cell clone (GenBank GI no. 10304701;
CDR3:CASRRSRSSYNEQFF) reported from our laboratory (35),
indicating that they may recognize similar antigenic determinants
located in vascular tissue. The CDR3 of clone 03-31 (CDR3:
CASSQGLYNEQFF) from patient AAA03 was substantially ho-
mologous to the CDR3 of a T cell clone (GenBank GI no. 12751193;
CDR3: CASSQGGYNEQFF) isolated from active psoriatic arthritis
joint fluid. Clone 03-17 (CDR3:CASSPGGGGANTEAFF) shared
substantial homology with a T cell clone (GenBank GI no. 13249236;
CDR3:CAWSRGGIGLNTEAFF) that has anti-snRNP activity. The
clonally expanded clone 00-03 (CDR3:CASSLVGGGVSYEQYF)
from AAA00 shared substantial homology with a T cell clone
(GenBank GI no. 241751; CDR3:CASSLTTGGGYEQYF) reactive
to superantigen staphylococcal enterotoxins. CDR3s of the re-
maining clonally expanded TCR transcripts were not highly ho-
mologous to T cell clones retrieved from the database.
Discussion
We report the presence of statistically significant clonal expansions
of T cells infiltrating AAA lesions of patients with AAA. PCR
amplification, followed by cloning and sequencing, revealed the
presence of multiple identical copies of b-chain TCR transcripts
Table VI. b-chain TCR transcripts (CDR3 region) expressed in purified CD8+ T cells from PBMCs of a healthy donor
Clone Vb N-Db-N Jb
Transcript Frequency in
Specimen; p Value
b-chain TCR transcripts amplified by NPA-PCR
NBCD808 C S A R D H A G E Y G Y T F Vb2.1Db2.1Jb1.2
tgcagtgctaga gatcacgcaggagaa tatggctacaccttc 1/19, NS
NBCD806 C S A N T G Q G T D N Q P Q H F Vb2.1Db1.1Jb1.5
tgcagtgcc aatacgggacaggggaccga caatcagccccagcatttt 1/19, NS
NBCD803 C S A S P G R D N S P L H F Vb2.1Db2.1Jb1.6
tgcagtgct agtcccggacgag ataattcacccctccacttt 1/19, NS
NBCD810 C S A R Q S N E Q F F Vb2.1Db1.1Jb2.1
tgcagtgctaga cagtc caatgagcagttcttc 1/19, NS
NBCD824 C S A S L G Q G A R T G E L F F Vb2.1Db1.1Jb2.2
tgcagtgct agtctgggacagggggcgcggact ggggagctgtttttt 1/19, NS
NBCD853 C S A R S F A L A G E T Q Y F Vb2.1Db2.1Jb2.5
tgcagtgctaga agtttcgcgctagcgggg gagacccagtacttc 1/19, NS
NBCD819 C S A L D R R S Y E Q Y F Vb2.1Db1.1Jb2.7
tgcagtgct cttgacaggcga tcctacgagcagtacttc 1/19, NS
NBCD820 C A S S T A T G G S Y N E Q F F Vb3.1Db1.1Jb2.1
tgtgccagcagt actgccacagggggc tcctacaatgagcagttcttc 1/19, NS
NBCD818 C S V W D Y G P E Q Y F Vb4.1Db2.1Jb2.7
tgcagcgtt tgggattatggacc cgagcagtacttc 1/19, NS
NBCD847 C A S T E G D W A G E L F F Vb5.1Db2.1Jb2.2
tgcgccagc actgagggggattggg ccggggagctgtttttt 1/19, NS
NBCD829 C A S S P G A S E Q Y F Vb5.2Db2.1Jb2.7
tgtgccagcagt ccgggggcatc cgagcagtacttc 1/19, NS
NBCD841 C A S S G E P G Q F F Vb5.3Db2.1Jb2.1
tgtgccagcagt ggggaaccgg ggcagttcttc 1/19, NS
NBCD821 C A S S K T G T G D T Q Y F Vb5.3Db2.1Jb2.3
tgtgccagcagt aagacaggaactgg agatacgcagtatttt 1/19, NS
NBCD830 C A S S Y P G L A G V I P E Q Y F Vb6.4Db2.1Jb2.7
tgtgccagcagt tatccgggactagcgggagtaatacc cgagcagtatttc 1/19, NS
NBCD816 C A S S L P S S E A L F Vb8.2Db2.1Jb1.1
tgtgccagcagt ctcccaagtt ctgaagctttgttt 1/19, NS
NBCD831 C A S S V R R Q Q L N T E A F F Vb14.1Db1.1Jb1.1
tgtgccagcagt gtgcgtcgacagcaattg aacactgaagctttcttt 1/19, NS
NBCD802 C A S S P Y S N Q P Q H F Vb18.1Db2.1Jb1.5
tgtgccagctca ccatat agcaatcagccccagcatttt 1/19, NS
NBCD828 C A S S L G I S S G I A G E L F F Vb21.3Db2.1Jb2.2
tgtgccagcagc ttagggatctcgtctggtatcg ccggggagctgtttttt 1/19, NS
NBCD814 C A S S P R G N T E A F F Vb22.1Db1.1Jb1.1
tgtgccag cagtccacggggg aacactgaagctttcttt 1/19, NS
Table VII. DNA-based typing for HLA-DRB1, HLA-DQA1, and HLA-DQB1 loci of patients with AAA
Sample DRB1-1 DRB1-2 DQA1-1 DQA1-2 DQB1-1 DQB1-2 DRbQ70
AAA02 03:01 11:04 05:01 05:05 02:01 03:01 +
AAA03 03:01 01:01 01:01 05:01 02:01 05:01 +
AAA04 04:01 07:01 02:01 03:01 02:02 03:02 +
AAA06 07:01 12:01 02:01 05:05 03:01 03:03 2
AAA09 01:01 07:01 01:01 02:01 02:02 05:01 +
AAA10 03:01 15:01 01:02 05:01 02:01 06:02 +

















in AAA lesions from 8 of 10 patients, demonstrating the presence
of monoclonal or oligoclonal populations of T cells. Additional
studies need to be carried out to determine whether clonally ex-
panded T cell populations are present in the peripheral blood of
patients with AAA, in addition to their presence in AAA lesions.
T cells are comprised of many different T cell clones. Each one
of them expresses a unique TCR on the cell surface that serves as
a unique fingerprint of that particular T cell clone (38). Each T cell
clone recognizes a different antigenic epitope through its unique
TCR. The TCR repertoire is very large. The maximum number of
different T cell clones expressing ab TCR was estimated to be on
the order of 1018 (38). The maximum theoretical number of dif-
ferent b-chain TCR transcripts is 1012 (38). However, only a small
portion of these cells survive thymic selection and became mature
T lymphocytes. For this reason, the size of the T cell repertoire in
the peripheral blood was estimated to be 106 different b-chain
TCR polypeptides, and each one of them pairs with $25 different
a-chain TCR polypeptides (reviewed in Ref. 27). The number of
T cell clones is very large and sufficient to recognize all possible
antigenic epitopes. Because of the large size of the T cell reper-
toire, the probability of finding, by chance, multiple identical
copies of a- or b-chain TCR transcripts in an independent sample
of T cells is negligible. Therefore, the presence of multiple
identical copies of a- or b-chain TCR transcripts must be the
result of specific Ag–driven proliferation and clonal expansion in
response to unidentified self- or nonself Ag(s).
Our studies support the hypothesis that AAA is a specific Ag–
driven T cell disease. We used sequencing analysis of TCR tran-
scripts after PCR amplification and cloning to test the hypothesis
that mononuclear cells infiltrating AAA lesions contain mono-
clonal or oligoclonal populations of T cells. Clonal expansions
of b-chain TCR transcripts were identified using NPA-PCR/Vb-
specific PCR, followed by cloning and sequencing. These results
were confirmed by an independent amplification method, two-
sided Vb-specific PCR, followed by cloning and sequencing, and
identical clonal expansions were obtained (Table II). Also, a-chain
TCR transcripts in AAA lesions were clonally expanded (unpub-
lished results). Preferential usage of Vb22 and Vb25 was reported
(42) in aneurysmic lesions from 10 of 14 patients with Marfan
syndrome or familial thoracic aortic aneurysms, as well as in
patients with sporadic thoracic aortic aneurysms.
Several lines of evidence suggest that AAA is an autoimmune
disease. Mononuclear cell infiltrates, comprised primarily of T cells
and monocytes, have been reported in AAA lesions (7–9). At this
time, it is not known whether more infiltrating T cells are present
in AAA lesions containing clonally expanded T cells (8 of 10
patients) versus in AAA lesions containing polyclonal T cells (2 of
10 patients). We have previously shown that higher numbers of
T cells infiltrating in vivo ovarian carcinoma human tumors cor-
relate well with HLA class I expression on ovarian tumor cells and
the ability of these T cells to expand in vitro in culture with rIL-2
to T cell lines with potential antitumor activity (43). These results
suggest the presence of higher numbers of infiltrating T cells in
these tumors in the presence of an immune response under conditions
of chronic inflammation. Many of these infiltrates express early
(CD69), intermediate (CD25, CD38), and late (CD45RO, HLA
class II) activation Ags, demonstrating the presence of an ongoing
immune response in AAA lesions (9) where the production of Th1
and Th2 cytokines has been reported (24–26). The role of Th1 and
Th2 cytokines in the pathogenesis of AAA remains to be eluci-
dated (reviewed in Ref. 6). gd TCR+ T cells also were clonally
expanded in AAA lesions, and this includes the various forms of
gd TCR+ T cells previously reported (9, 44). The frequency and
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































ripheral blood of patients with AAA were significantly lower
versus with those in patients with abdominal aortic atherosclerotic
occlusive disease or healthy donors (45). These results demon-
strate impaired immunoregulation in AAA, which may play a role
in the pathogenesis of the disease. Elevated levels of CD4+CD282
cells were found in the peripheral blood and AAA lesions of
patients with AAA (46). These T cells produce high levels of IFN-g
and perforin and may be responsible, among other cell populations,
for causing injury to the aorta. APCs, such as dendritic cells,
monocytes, and B cells, are present (7–9) in this chronic inflam-
matory environment and play a critical role in the propagation of
the disease. This chronic inflammation is typical of that observed
in autoimmune diseases (47, 48) and the immune response to
tumors (49).
Along the same lines and of considerable significance is the
association of particular HLA class I (HLA-A2, HLA-B61) and
class II (HLA-DRB1*02, HLA-DRB1*04) alleles with AAA (10,
11, 50). Six of 10 patients with AAA who were included in this
study were typed for HLA-DRB1, HLA-DQA1, and HLA-DQB1
loci using DNA-based approaches. Five of these six patients
expressed DRB1 alleles positive for the DRbGln[70] amino acid
residue, which is associated with inflammatory AAA (11). Amino
acid residue 70, together with amino acids in positions 67, 71, and
74, form an important peptide-binding pocket (#4) in HLA-DRB1
(51, 52). The shared epitope sequence at position 70–74 of HLA-
DRB1 alleles is strongly associated with susceptibility to RA (53–
56). Specifically, the shared epitope Arg-Ala-Ala sequence at
positions 72–74 of the HLA-DRB1 alleles is associated with a
high risk for developing RA, and this risk is modulated by amino
acids in positions 70 and 71. Gln or Arg in position 70 and Lys in
position 71 confer the highest risk (53–56). The association of
amino acid Gln in position 70 with susceptibility to RA, and the
presence of Gln in position 70 of HLA-DRB1 alleles in patients
with AAA, provides an additional argument that AAA is an au-
toimmune disease. Amino acid 70 is located in a critical position
at the entrance of pocket 4, affecting the binding of the ab TCR to
the HLA-DRB1:peptide complex. Replacement of the negatively
charged Asp, which is usually present in position 70 in many HLA-
DRB1 alleles and favors interactions with peptide side chains that
are positively charged, by the noncharged amino acid Gln radically
changes the binding characteristics of the HLA-DRB1 site. The
studies reported in this article may provide the basis for the iden-
tification of the three molecular entities responsible for eliciting
immune responses in AAA: namely, the ab TCR, HLA-DRbGln
[70], and the AAA-associated peptides.
As mentioned earlier, a number of putative AAA Ags of self
origin (reviewed in Refs. 4, 12–18) and nonself origin (19–22) have
been identified. Initiation and propagation of AAA are the two
phases of the disease that may be driven by different, although
cross-reactive, antigenic determinants. Production of IFN-g by
CD4+ T cells in a murine model of AAA (25) and our results
support a critical role for a specific Ag–driven immune response in
the pathogenesis of AAA. It is possible that AAA is initiated by
an immune response against a nonself antigenic epitope of a
microorganism, such as those mentioned above, which cross-reacts
with an epitope of a self-Ag (12, 13, 17, 21, 57, 58). After the
microorganism is cleared, the immune response is propagated by
molecular mimicry in response to cross-reacting antigenic epitope(s)
of self-Ag(s) of the host. Molecular mimicry is defined as the
sharing of cross-reactive antigenic epitopes between microorganisms
and host Ags (23), and it is responsible for a number of diseases.
Although the clonal expansions of T cells in AAA lesions that
we report in this article may not provide the necessary proof that
AAA is initiated by a specific Ag–driven T cell response, they do
provide strong evidence suggesting that a specific Ag–driven T cell
response is critical for the propagation of the disease. Again, this
type of immune response may involve molecular mimicry. It could
be argued that the clonal expansions of T cells that we found in
AAA lesions may represent an immune response to matrix deg-
radation products present in AAA lesions and that this immune
response may be a less important epiphenomenon in the patho-
genesis of AAA. This possibility appears unlikely. T cells rec-
ognize peptides in association with self-MHC, and self-antigenic
determinants do not necessarily require degradation of the matrix
to be presented to self T cells. T cell clones that could recognize
self-determinants are eliminated from the T cell repertoire during
thymic selection. It is more likely that molecular mimicry mecha-
nisms (reviewed in Ref. 23) are responsible for the T cell clonal
expansions that we report in this article. Because these T cell clones
may recognize cross-reactive antigenic epitopes between micro-
organisms and host Ags, they may escape elimination during thymic
selection.
The presence of monoclonal/oligoclonal T cells infiltrating AAA
lesions provides strong evidence that AAA is likely a specific Ag–
driven autoimmune T cell disease. The identification of the clonally
expanded TCR transcripts in these AAA lesions may permit the
identification of the self or nonself Ags recognized by these clonally
expanded T cells in AAA. Critical evidence for increasing our
understanding of the pathogenesis of the disease may be provided
by the identification of the Ag(s) recognized by the clonally ex-
panded T cells in AAA lesions. These Ags may play a key role in
the initiation and/or the propagation of the disease.
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